EYPT — EyePoint, Inc.

Nasdaq · Unknown · Unknown · CIK 1314102 ·
Last close
$4.87
Market Cap
$419.85M
52W High
$15.92
52W Low
$3.95
ADV30
4,594,944
Next earnings
2026-11-04
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 507,000 507,000 -97,380,000 -94,470,000 228,191,000 110,458,000 61,780,000
Mar 2026 696,000 168,000 -87,226,000 -84,832,000 288,217,000 77,712,000 57,745,000
Dec 2025 620,000 245,000 -70,345,000 -67,609,000 363,996,000 101,821,000 57,883,000
Sep 2025 966,000 245,000 -62,025,000 -59,732,000 251,695,000 74,577,000 51,513,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-267,539,000
Investing CF
$88,109,000
Financing CF
$171,984,000
CapEx
$-4,001,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.50
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,284,280,000
Inventory
$1,882,000
Receivables
$86,000
ST Investments
$70,014,000
EBIT TTM
$-305,192,000
Pretax Income TTM
$-306,507,000
Interest Exp TTM
$14,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,788,000
EBITDA
$-314,376,000
Free Cash Flow
$-155,010,624
Enterprise Value
$477,462,080
Total Cash
$45,261,000
Total Debt
$17,621,000
Shares Out
86,212,138
Trailing EPS
$-3.75
Book Value
$0.40
ROE
-148.7%
ROA
-74.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 31,371,000 -243,434,000 -231,962,000 363,996,000 57,883,000 -240,110,000
Dec 2024 43,273,000 -145,854,000 -130,870,000 418,465,000 81,964,000 -126,226,000
Dec 2023 46,018,000 -75,067,000 -70,795,000 355,184,000 88,861,000 1,875,000
Dec 2022 41,404,000 -78,938,000 -102,254,000 180,356,000 83,988,000 -65,005,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.76

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $4.87 · call volume: 10,303 · put volume: 2,043
Expected Move to 2026-12-18: ±$4.34 (89.12%) — implied range $0.53$9.21 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
FINS Angel Oak Financial Strategies Income Term Trust $420.05M $12.57
DFP Flaherty & Crumrine Dynamic Preferred & Income Fund Inc $423.70M $20.63
HPI JOHN HANCOCK PREFERRED INCOME FUND $424.12M $15.83
EVN Eaton Vance Municipal Income Trust $427.57M $10.71
NXG NXG NextGen Infrastructure Income Fund $411.41M $56.11

News headlines (Yahoo Finance, 1h cache)

EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says
2026-08-18 15:09 · Yahoo
EyePoint’s Duravyu falls short to Eylea in Phase III trial
2026-08-18 14:40 · Yahoo
EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’
2026-08-18 11:57 · Yahoo
EyePoint (EYPT) LUGANO Data Resets The Story, Is It A Bargain?
2026-08-18 06:12 · Yahoo
Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today?
2026-08-18 03:00 · Yahoo
The Surprising Reason EyePoint Just Crashed 67%, Sacrificing A Breakout
2026-08-17 20:33 · Yahoo
EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden
2026-08-17 14:56 · Yahoo
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
2026-08-05 13:00 · Yahoo
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
2026-08-05 11:00 · Yahoo
These 2 Stocks Are Setting Off Technical Alarm Bells with $1,000+ Price Tags. Here’s the Company I’d Bet on for the Long Term.
2026-08-18 20:22 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.